U.S. government launches first federally funded ibogaine trials for opioid addiction and PTSD
The Trump administration announced the start of the United States' first government‑funded clinical trials of ibogaine, a psychedelic compound being investigated for its potential to treat opioid use disorder and post‑traumatic stress disorder.
The trials represent a new federal commitment to explore psychedelic therapies as part of the nation’s response to the opioid crisis and mental‑health challenges.
If successful, the research could open pathways for regulatory approval and broader clinical use of ibogaine, marking a significant shift in how psychedelic drugs are evaluated in the United States.
This writeup was produced by pharmadog from original reporting by STAT. The original article may no longer be reachable at its published URL.
Original headline: “STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that